Showing 49 to 60 of 151 results
BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported
BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.
BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported
BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.
Progress
36% Bias Score
Halozyme Sues Merck Over Injectable Keytruda
Merck's new injectable Keytruda faces a lawsuit from Halozyme, delaying its planned October 1 launch and highlighting upcoming patent expirations in 2028. The suit challenges Merck's use of Halozyme's hyaluronidase technology in the new injectable formulation, and Merck has said it is meritless.
Halozyme Sues Merck Over Injectable Keytruda
Merck's new injectable Keytruda faces a lawsuit from Halozyme, delaying its planned October 1 launch and highlighting upcoming patent expirations in 2028. The suit challenges Merck's use of Halozyme's hyaluronidase technology in the new injectable formulation, and Merck has said it is meritless.
Progress
40% Bias Score
AstraZeneca Shifts US Drug Production Amid Trade Tariffs, Warns Europe
AstraZeneca, reporting a 13% revenue rise to $15.6 billion in Q1 2024, is moving some US drug production from Europe to the US due to trade tariffs, warning Europe risks losing out to the US and China without increased healthcare spending.
AstraZeneca Shifts US Drug Production Amid Trade Tariffs, Warns Europe
AstraZeneca, reporting a 13% revenue rise to $15.6 billion in Q1 2024, is moving some US drug production from Europe to the US due to trade tariffs, warning Europe risks losing out to the US and China without increased healthcare spending.
Progress
44% Bias Score
Sanofi to Create 300 Jobs with New Barcelona Innovation Hub
Sanofi will open a new innovation and AI hub in Barcelona's 22@ district, creating 300 jobs by the end of the year, focusing on process excellence and digitalization, as part of its strategy to increase its presence in Spain.
Sanofi to Create 300 Jobs with New Barcelona Innovation Hub
Sanofi will open a new innovation and AI hub in Barcelona's 22@ district, creating 300 jobs by the end of the year, focusing on process excellence and digitalization, as part of its strategy to increase its presence in Spain.
Progress
60% Bias Score
Eli Lilly's Weight-Loss Pill Poised for Market Disruption
Eli Lilly's new weight-loss pill, showing 8% weight loss in trials, offers a more accessible treatment option compared to injectables, potentially reaching a larger patient base and generating \$100 billion in sales by 2030.
Eli Lilly's Weight-Loss Pill Poised for Market Disruption
Eli Lilly's new weight-loss pill, showing 8% weight loss in trials, offers a more accessible treatment option compared to injectables, potentially reaching a larger patient base and generating \$100 billion in sales by 2030.
Progress
64% Bias Score
Trump Executive Order Seeks to Lower Prescription Drug Prices
President Trump signed an executive order to lower prescription drug prices by modifying the Medicare drug price negotiation program, expediting generic approvals, increasing low-cost imports, and potentially reclassifying some drugs for over-the-counter sales, specifically mentioning insulin and ep...
Trump Executive Order Seeks to Lower Prescription Drug Prices
President Trump signed an executive order to lower prescription drug prices by modifying the Medicare drug price negotiation program, expediting generic approvals, increasing low-cost imports, and potentially reclassifying some drugs for over-the-counter sales, specifically mentioning insulin and ep...
Progress
40% Bias Score
Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback
Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...
Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback
Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...
Progress
36% Bias Score
Mexico City Invalidates Pharmaceutical Company, Investigates 16 More for Irregularities
The Mexico City government invalidated pharmaceutical company Biomedics and is investigating 16 more for irregularities in a medication purchase process, resulting in an annulment due to 13 billion pesos in overcharges; however, there have been no disruptions to supply.
Mexico City Invalidates Pharmaceutical Company, Investigates 16 More for Irregularities
The Mexico City government invalidated pharmaceutical company Biomedics and is investigating 16 more for irregularities in a medication purchase process, resulting in an annulment due to 13 billion pesos in overcharges; however, there have been no disruptions to supply.
Progress
40% Bias Score
U.K. Seeks U.S. Trade Deal, Targeting Tariff Reductions
U.K. Chancellor Rachel Reeves stated that Britain is actively negotiating a trade deal with the U.S., prioritizing tariff reductions on automobiles and pharmaceuticals, while also emphasizing the importance of a balanced agreement and technology collaboration; meetings with U.S. officials are underw...
U.K. Seeks U.S. Trade Deal, Targeting Tariff Reductions
U.K. Chancellor Rachel Reeves stated that Britain is actively negotiating a trade deal with the U.S., prioritizing tariff reductions on automobiles and pharmaceuticals, while also emphasizing the importance of a balanced agreement and technology collaboration; meetings with U.S. officials are underw...
Progress
40% Bias Score
Roche to Invest \$50 Billion in US Production
Roche, a Swiss pharmaceutical company, announced a \$50 billion investment in US production facilities over five years, creating 12,000 jobs, to mitigate trade war risks and strengthen its US market position, following a similar investment by Novartis.
Roche to Invest \$50 Billion in US Production
Roche, a Swiss pharmaceutical company, announced a \$50 billion investment in US production facilities over five years, creating 12,000 jobs, to mitigate trade war risks and strengthen its US market position, following a similar investment by Novartis.
Progress
32% Bias Score
Roche to Invest \$50 Billion in US, Create 12,000 Jobs
Roche, a Swiss pharmaceutical company, announced a \$50 billion investment in the US over five years, creating 12,000 jobs, potentially in response to recent US tariff announcements and aimed at increasing US-based manufacturing and exports.
Roche to Invest \$50 Billion in US, Create 12,000 Jobs
Roche, a Swiss pharmaceutical company, announced a \$50 billion investment in the US over five years, creating 12,000 jobs, potentially in response to recent US tariff announcements and aimed at increasing US-based manufacturing and exports.
Progress
36% Bias Score
US Launches Investigations into Semiconductor and Pharmaceutical Imports, Citing National Security
The U.S. Department of Commerce launched investigations into semiconductor and pharmaceutical imports, citing national security risks, potentially leading to new tariffs under Section 232 of the Trade Expansion Act of 1962, impacting global supply chains and trade relations.
US Launches Investigations into Semiconductor and Pharmaceutical Imports, Citing National Security
The U.S. Department of Commerce launched investigations into semiconductor and pharmaceutical imports, citing national security risks, potentially leading to new tariffs under Section 232 of the Trade Expansion Act of 1962, impacting global supply chains and trade relations.
Progress
36% Bias Score
Showing 49 to 60 of 151 results